Motolimod / VTX2337

Target: Toll-Like Receptor | Disease State: Cancer

Introduction / Brief Description

MotolimodĀ is a small molecule agonist of toll-like receptor 8 invented by Array and licensed to VentiRx. In February 2017, Celgene acquired VentiRx and the motolimod program.

Motolimod is being evaluated in a randomized Phase 2 trial in patients with ovarian cancer.

Clinical TrialsĀ 

To learn more about motolimod clinical trials, click here.

Publications and Presentations



Clinical Cancer Research

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC

H. Lu, et al

To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.